The American Society of Clinical Oncology annual meeting kicks off today in Chicago, with highly anticipated presentations ...

Regeneron and Sanofi’s Dupixent will have to wait until September 2024 for the FDA to decide whether to expand the drug’s ...

As evidenced by this week’s buyouts by J&J and Merck, Big Pharma appears to have found a sweet spot favoring smaller deals ...

Novartis’ Scemblix posted stronger results with fewer discontinuation rates than both its own Gleevec and a stronger ...

Gilead Sciences announced on Thursday that its antibody-drug conjugate Trodelvy failed to reach the primary endpoint in a ...

The Roivant spinout is shifting its attention away from batoclimab to anti-FcRn candidate IMVT-1402, which will target autoimmune disorders, while allowing argenx’s Myasthenia Gravis drug Vyvgart to ...

The American Society of Clinical Oncology (ASCO)’s annual meeting kicks off Friday in Chicago, with more than 5,000 abstracts ...

As BioNTech struggles to find its footing in a post-pandemic world, the biotech has secured $145 million from the Coalition ...

Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two ...

Despite Biohaven’s bispecific protein degrader cutting autoantibody IgG levels by up to 37% in an early-stage study, ...

Additional analyses from BridgeBio Pharma’s late-stage study show the oral drug candidate’s improved clinical outcomes in ...

Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for attention deficit hyperactivity disorder in pediatric patients.